Sage Therapeutics, Inc. (NASDAQ:SAGE) Receives $12.83 Average PT from Analysts

Sage Therapeutics, Inc. (NASDAQ:SAGE) has received an average recommendation of “Hold” from the twenty-one research firms that are presently covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a sell recommendation, seventeen have given a hold recommendation and two have given a buy recommendation to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $12.83.

SAGE has been the topic of a number of research reports. Robert W. Baird dropped their price objective on Sage Therapeutics from $13.00 to $9.00 and set a “neutral” rating on the stock in a research note on Wednesday, October 9th. Bank of America dropped their price target on shares of Sage Therapeutics from $11.00 to $6.00 and set an “underperform” rating on the stock in a research report on Wednesday, October 9th. Oppenheimer reduced their price objective on shares of Sage Therapeutics from $9.00 to $8.00 and set a “market perform” rating for the company in a research report on Wednesday, October 30th. StockNews.com downgraded shares of Sage Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, October 31st. Finally, JPMorgan Chase & Co. decreased their price target on shares of Sage Therapeutics from $12.00 to $10.00 and set a “neutral” rating on the stock in a research report on Tuesday, August 6th.

Institutional Trading of Sage Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the business. Bellevue Group AG raised its holdings in shares of Sage Therapeutics by 27.1% during the 1st quarter. Bellevue Group AG now owns 4,465,544 shares of the biopharmaceutical company’s stock valued at $83,684,000 after purchasing an additional 952,193 shares in the last quarter. Federated Hermes Inc. bought a new position in Sage Therapeutics during the second quarter valued at about $7,281,000. Renaissance Technologies LLC lifted its position in shares of Sage Therapeutics by 1,476.6% in the second quarter. Renaissance Technologies LLC now owns 553,396 shares of the biopharmaceutical company’s stock worth $6,010,000 after buying an additional 518,296 shares during the last quarter. State Street Corp boosted its stake in shares of Sage Therapeutics by 18.2% during the 3rd quarter. State Street Corp now owns 2,926,239 shares of the biopharmaceutical company’s stock worth $21,127,000 after acquiring an additional 451,377 shares in the last quarter. Finally, Cubist Systematic Strategies LLC increased its holdings in shares of Sage Therapeutics by 831.2% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 489,089 shares of the biopharmaceutical company’s stock valued at $5,312,000 after acquiring an additional 436,566 shares during the last quarter. 99.22% of the stock is currently owned by institutional investors and hedge funds.

Sage Therapeutics Stock Down 1.4 %

SAGE stock opened at $5.47 on Friday. The company has a market capitalization of $334.60 million, a P/E ratio of -0.98 and a beta of 0.92. The company has a 50-day simple moving average of $6.49 and a 200 day simple moving average of $8.81. Sage Therapeutics has a fifty-two week low of $4.62 and a fifty-two week high of $28.26.

Sage Therapeutics (NASDAQ:SAGE) last posted its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported ($1.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.52) by ($0.01). Sage Therapeutics had a negative net margin of 317.29% and a negative return on equity of 50.29%. The company had revenue of $11.87 million during the quarter, compared to the consensus estimate of $10.80 million. During the same quarter last year, the business earned ($2.81) earnings per share. The company’s revenue was up 337.1% on a year-over-year basis. Equities analysts anticipate that Sage Therapeutics will post -6.53 EPS for the current year.

About Sage Therapeutics

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.